MX2011003304A - Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa. - Google Patents
Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa.Info
- Publication number
- MX2011003304A MX2011003304A MX2011003304A MX2011003304A MX2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A MX 2011003304 A MX2011003304 A MX 2011003304A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- identifier
- land mobile
- mobile network
- network
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims description 17
- 230000001413 cellular effect Effects 0.000 claims description 12
- 239000013589 supplement Substances 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000005233 imidazopyridazines Chemical class 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10404508P | 2008-10-09 | 2008-10-09 | |
| PCT/US2009/059968 WO2010042699A1 (en) | 2008-10-09 | 2009-10-08 | Imidazopyridazinecarbonitriles useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011003304A true MX2011003304A (es) | 2011-04-21 |
Family
ID=41718919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011003304A MX2011003304A (es) | 2008-10-09 | 2009-10-08 | Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8252795B2 (enExample) |
| EP (1) | EP2350081B1 (enExample) |
| JP (1) | JP5560278B2 (enExample) |
| KR (1) | KR20110075010A (enExample) |
| CN (1) | CN102245609B (enExample) |
| AR (1) | AR073818A1 (enExample) |
| AU (1) | AU2009302360B2 (enExample) |
| BR (1) | BRPI0920135A2 (enExample) |
| CA (1) | CA2739782A1 (enExample) |
| CL (1) | CL2011000777A1 (enExample) |
| CO (1) | CO6361936A2 (enExample) |
| CY (1) | CY1114539T1 (enExample) |
| DK (1) | DK2350081T3 (enExample) |
| EA (1) | EA018163B1 (enExample) |
| ES (1) | ES2426951T3 (enExample) |
| HR (1) | HRP20130787T1 (enExample) |
| IL (1) | IL211693A (enExample) |
| MX (1) | MX2011003304A (enExample) |
| NZ (1) | NZ591712A (enExample) |
| PE (1) | PE20110411A1 (enExample) |
| PL (1) | PL2350081T3 (enExample) |
| PT (1) | PT2350081E (enExample) |
| SI (1) | SI2350081T1 (enExample) |
| SM (1) | SMT201300109B (enExample) |
| TW (1) | TWI491610B (enExample) |
| WO (1) | WO2010042699A1 (enExample) |
| ZA (1) | ZA201102423B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009100375A1 (en) * | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US9587033B2 (en) | 2010-11-15 | 2017-03-07 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting TNK-1 |
| JP5824065B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| EP2651948A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| US20140323519A1 (en) * | 2011-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| PT3008062T (pt) | 2013-06-11 | 2017-06-07 | Bayer Pharma AG | Derivados de profármaco de triazolopiridinas substituídas |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US10479793B2 (en) | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| EP3474855B1 (en) | 2016-06-24 | 2022-01-26 | Polaris Pharmaceuticals, Inc. | Ck2 inhibitors, compositions and methods thereof |
| US10696651B2 (en) * | 2016-08-10 | 2020-06-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102611856B1 (ko) | 2016-11-17 | 2023-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제 |
| MX2019010302A (es) | 2017-03-30 | 2019-11-21 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1. |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| BR112020013313B1 (pt) | 2017-12-29 | 2023-10-31 | Jiangsu Flag Chemical Industry Co., Ltd | Composto de pirazolamida de fórmula geral i, composto de fórmula ii, método para preparar um composto de fórmula geral i, uso do composto de fórmula geral i, composição inseticida e método para controlar pragas |
| WO2019128871A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| CN109988150B (zh) | 2017-12-29 | 2022-04-12 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| KR20200115620A (ko) * | 2018-01-29 | 2020-10-07 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| MX2021000293A (es) | 2018-07-09 | 2021-07-15 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos antihelminticos. |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| ES2987809T3 (es) * | 2019-03-05 | 2024-11-18 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa |
| BR112021018631A2 (pt) | 2019-03-19 | 2021-11-23 | Boehringer Ingelheim Animal Health Usa Inc | Compostos anti-helmínticos de aza-benzotiofeno e aza-benzofurano |
| EP3958865B1 (en) | 2019-04-24 | 2025-12-10 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| US20240307362A1 (en) | 2019-04-24 | 2024-09-19 | Bayer Aktiengesellschaft | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS |
| US20220298157A1 (en) | 2019-04-24 | 2022-09-22 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| CA3177214A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| WO2021242581A1 (en) | 2020-05-29 | 2021-12-02 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
| KR20230142557A (ko) * | 2021-02-03 | 2023-10-11 | 사노피 | 이미다조[4,5-d]피리다진의 유도체, 이의 제법 및 이의 치료적 응용 |
| UY39995A (es) | 2021-11-01 | 2023-05-15 | Boehringer Ingelheim Vetmedica GmbH | Compuestos de pirrolopiridazina como antihelmínticos |
| MX2024009105A (es) * | 2022-01-25 | 2024-09-18 | Kinnate Biopharma Inc | Inhibidores de las cinasas cdk4/6. |
| US20260055114A1 (en) * | 2022-08-18 | 2026-02-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases |
| CN115947756B (zh) * | 2022-12-13 | 2025-08-01 | 西湖大学 | 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2273369T3 (es) | 1996-08-28 | 2007-05-01 | Pfizer Inc. | Derivados 6,5 heterobiciclicos sustituidos. |
| JP3729343B2 (ja) | 2000-04-27 | 2005-12-21 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| ATE362475T1 (de) * | 2003-12-31 | 2007-06-15 | Schering Plough Ltd | Bekämpfng von parasiten in tieren durch anwendung von imidazo(1,2-b)pyridazinderivaten |
| WO2005080355A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| CN101048158A (zh) * | 2004-08-13 | 2007-10-03 | 健泰科生物技术公司 | 利用atp的酶的噻唑－类抑制剂 |
| CA2594325A1 (en) * | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | Condensed imidazole compound and use thereof |
| AR056191A1 (es) | 2005-08-23 | 2007-09-26 | Idenix Phatmaceuticals Inc | Anillo de nucleosidos de siete miembros como inhibidores de la replica viral, metodos para su sintesis, composiciones farmaceuticas que los contienen y su uso en el tratamiento de infecciones con virus de la familia flaviviridae |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| JP5238697B2 (ja) * | 2006-08-04 | 2013-07-17 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| EP1911451A1 (en) * | 2006-10-10 | 2008-04-16 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Protein-kinase CK2 inhibitors and their therapeutic applications |
| RU2009120388A (ru) * | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Имидазопиридазины в качестве ингибиторов липидкиназы |
| KR20100019489A (ko) * | 2007-05-09 | 2010-02-18 | 노파르티스 아게 | Ｐｉ３ｋ 지질 키나제 억제제로서의 치환된 이미다조피리다진 |
| WO2009100375A1 (en) * | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
-
2009
- 2009-10-01 TW TW098133429A patent/TWI491610B/zh not_active IP Right Cessation
- 2009-10-08 CN CN200980149133.2A patent/CN102245609B/zh not_active Expired - Fee Related
- 2009-10-08 HR HRP20130787AT patent/HRP20130787T1/hr unknown
- 2009-10-08 EA EA201100580A patent/EA018163B1/ru not_active IP Right Cessation
- 2009-10-08 PE PE2011000814A patent/PE20110411A1/es not_active Application Discontinuation
- 2009-10-08 PL PL09740573T patent/PL2350081T3/pl unknown
- 2009-10-08 DK DK09740573.2T patent/DK2350081T3/da active
- 2009-10-08 JP JP2011531168A patent/JP5560278B2/ja not_active Expired - Fee Related
- 2009-10-08 BR BRPI0920135A patent/BRPI0920135A2/pt not_active IP Right Cessation
- 2009-10-08 KR KR1020117010394A patent/KR20110075010A/ko not_active Ceased
- 2009-10-08 ES ES09740573T patent/ES2426951T3/es active Active
- 2009-10-08 MX MX2011003304A patent/MX2011003304A/es active IP Right Grant
- 2009-10-08 SI SI200930729T patent/SI2350081T1/sl unknown
- 2009-10-08 PT PT97405732T patent/PT2350081E/pt unknown
- 2009-10-08 AU AU2009302360A patent/AU2009302360B2/en not_active Ceased
- 2009-10-08 US US12/575,589 patent/US8252795B2/en active Active
- 2009-10-08 NZ NZ591712A patent/NZ591712A/xx not_active IP Right Cessation
- 2009-10-08 EP EP09740573.2A patent/EP2350081B1/en not_active Not-in-force
- 2009-10-08 WO PCT/US2009/059968 patent/WO2010042699A1/en not_active Ceased
- 2009-10-08 CA CA2739782A patent/CA2739782A1/en not_active Abandoned
- 2009-10-09 AR ARP090103910A patent/AR073818A1/es unknown
-
2011
- 2011-03-10 IL IL211693A patent/IL211693A/en not_active IP Right Cessation
- 2011-03-31 ZA ZA2011/02423A patent/ZA201102423B/en unknown
- 2011-04-07 CO CO11043111A patent/CO6361936A2/es active IP Right Grant
- 2011-04-07 CL CL2011000777A patent/CL2011000777A1/es unknown
-
2012
- 2012-07-19 US US13/552,795 patent/US20120283241A1/en not_active Abandoned
-
2013
- 2013-09-30 CY CY20131100844T patent/CY1114539T1/el unknown
- 2013-10-02 SM SM201300109T patent/SMT201300109B/xx unknown
-
2014
- 2014-02-27 US US14/191,861 patent/US9371328B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011003304A (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de cinasa. | |
| CN105025396B (zh) | 实现专网与公网对讲机通信的方法、系统及集群云基站 | |
| CN103220749B (zh) | 接入等级检查方法和装置 | |
| CA2739865C (en) | Method for operating a closed subscriber group (csg) cell for open network access | |
| RU2014102240A (ru) | Система мобильной связи | |
| KR101122189B1 (ko) | 비공개 가입자 그룹 아이디 비교를 줄이기 위한 방법 | |
| WO2008106360A3 (en) | Femtocell integration into the macro network | |
| US20230319756A1 (en) | Disaster roaming for plmn | |
| US20130148565A1 (en) | Mobile radio communications device for closed subscriber group management | |
| CN102378260A (zh) | 一种移动负载均衡实现方法和装置 | |
| CA2729632C (en) | Method for defining a range for closed subscriber group identities for an open network access point | |
| KR20110068015A (ko) | 하이브리드 셀을 지원하는 기지국의 페이징 최적화 방법 및 장치 | |
| WO2010069240A1 (zh) | 移动终端接入开放模式家庭基站的方法及系统 | |
| CN102857878B (zh) | 一种集群建立方法及系统及网络侧设备及终端 | |
| CN102857982B (zh) | 接入处理方法及装置 | |
| CN102612114B (zh) | 标识更新处理方法、家庭基站、网关和接入网系统 | |
| CN103634742B (zh) | 呼叫请求消息的发送、接收方法及装置 | |
| CN105721270B (zh) | 一种集群通信虚拟网的控制方法 | |
| CN101674539A (zh) | 一种信息推送和呼叫转接的方法、系统及装置 | |
| CN105992207B (zh) | 一种ue鉴权方法和装置以及用于ue鉴权的方法和装置 | |
| SE547842C2 (en) | A method for identifying and separating legitimate attempts to register to a network from fraudulent | |
| CN102547696A (zh) | 毫微微小区基站中用于通信的方法和装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |